Zenas BioPharma is a clinical stage global biopharmaceutical company engaged in the discovery and development of immunology based therapies for patients with autoimmune diseases. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit B cell activity without depletion, and it is being studied in immunoglobulin G4 related disease, relapsing remitting multiple sclerosis, and systemic lupus erythematosus. The company also advances other pipeline assets such as the oral BTK inhibitor orelabrutinib and early stage programs targeting IL 17 and TYK2 pathways.

Zenas BioPharma has not yet generated any revenue from product sales because none of its candidates have received regulatory approval. The company derives income from upfront licensing payments, milestone payments, and potential royalties under agreements with partners such as Bristol Myers Squibb for obexelimab in certain Asian markets, InnoCare for orelabrutinib and related molecules, and Zai for regional rights to ZB001 in Greater China. These arrangements may provide additional financial milestones upon achievement of development, regulatory, or commercial goals.

Zenas BioPharma positions itself within the competitive immunology landscape by focusing on novel mechanisms that aim to modulate immune pathways without causing broad immunosuppression. Its competitors include established players such as Roche with Ocrevus, Novartis with Kesimpta, Amgen with Uplizna, and Bristol Myers Squibb with Zeposia, all of which offer approved B cell or immunomodulatory therapies for similar indications. The company seeks to differentiate its candidates through differentiated mechanisms of action, such as obexelimab’s reversible B cell inhibition and orelabrutinib’s central nervous system penetration, which may address unmet needs in autoimmune and neurodegenerative diseases.

Although Zenas BioPharma currently has no approved products, its anticipated customers will include patients suffering from autoimmune conditions, neurologists, rheumatologists, and other specialists who treat these diseases, as well as hospitals, infusion centers, and health insurance providers that determine coverage and reimbursement. The company expects to serve these stakeholders through direct sales teams or distribution partners once its therapies reach the market.